Revolution Medicines, Inc. Increase (Decrease) in Deferred Liabilities
Revolution Medicines, Inc. (RVMD) reported Increase (Decrease) in Deferred Liabilities of -$513.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2022-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredLiabilities · last filed 2022-02-28
- Revolution Medicines, Inc. increase (decrease) in deferred liabilities for the quarter ending 2019-12-31 was -$140.00K.
- Revolution Medicines, Inc. increase (decrease) in deferred liabilities for the quarter ending 2019-09-30 was -$141.00K.
- Revolution Medicines, Inc. increase (decrease) in deferred liabilities for the quarter ending 2019-06-30 was -$136.00K.
- Revolution Medicines, Inc. increase (decrease) in deferred liabilities for the quarter ending 2019-03-31 was -$96.00K.
- Revolution Medicines, Inc. increase (decrease) in deferred liabilities for fiscal 2019 was -$513.00K.
- Revolution Medicines, Inc. increase (decrease) in deferred liabilities for fiscal 2018 was -$552.00K.
| Period end | Increase (Decrease) in Deferred Liabilities 3 month | Increase (Decrease) in Deferred Liabilities 6 month | Increase (Decrease) in Deferred Liabilities 9 month | Increase (Decrease) in Deferred Liabilities 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$281.00K derived: sum of 2 quarters · filed 2022-02-28 | -$417.00K derived: sum of 3 quarters · filed 2022-02-28 | -$513.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | -$141.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$277.00K derived: sum of 2 quarters · filed 2020-11-12 | -$373.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$136.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$232.00K 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | -$96.00K 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | -$552.00K 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |